Tesamorelin: preparation and storage
Intended for research use only. Not a medicinal product.
Contents (11 sections)
A GHRH analogue with an N-terminal modification
Tesamorelin is a synthetic human GHRH/GRF analogue: its 44-residue chain carries an N-terminal hexenoyl modification. It is distinct from native GHRH, short modified GRF(1-29) and CJC-1295 DAC. Check full length, modification, acetate form and mass-labeling convention. GHRH-receptor activity does not establish structural identity. Comparisons with other secretagogues must account for different mechanisms: tesamorelin does not become a ghrelin-receptor agonist because both pathways can influence GH secretion.
Excipient controls for formulated standards
When comparing tesamorelin formulations, controls must match actual sample composition. One water blank cannot separate hydroxypropyl-betadex effects from polysorbate effects. Chromatography needs background and recovery checks; cell assays need viability and basal-signal checks. Perform these before attributing differences to peptide activity. With an unknown formulation, the comparison concerns whole materials rather than purified tesamorelin forms under established equivalent conditions.
Salt mass and active-component content
Official descriptions distinguish tesamorelin active-component mass from acetate-salt mass. Pharmaceutical lyophilizates also contain substantial excipients, so total dry-residue mass is not tesamorelin mass. Establish whether the vial number denotes peptide, salt or mixture. HPLC purity without mass-content determination does not resolve water and counterion uncertainty. Comparing pure standard and formulated material requires accounting for calibration matrices rather than simply matching labeled milligrams.
Egrifta SV and WR illustrate formulation effects
Official Egrifta SV and Egrifta WR labels describe different formulations, excipients and preparation. SV includes histidine, mannitol, sucrose and polysorbate; WR uses a different composition including hydroxypropyl betadex. The same active-ingredient name therefore does not make finished-product conditions interchangeable. Laboratory powder without those components is another distinct form. Do not transfer a particular medicine’s temperature limits or post-reconstitution lifetime to it. Require the reagent’s own specification and validation of the chosen analytical matrix.
Mass calculations and working dilutions
An arithmetic example, not a solubility prescription: 2 mg in a final volume of 4 mL gives 0.5 mg/mL, or 500 micrograms/mL. Adding 20 microliters of that stock to 980 microliters of compatible matrix gives 10 micrograms/mL. Then 100 microliters of this solution plus 900 microliters of matrix gives 1 microgram/mL. Use the final volume in the calculation. If the certificate separately establishes peptide mass fraction, apply it according to the labeling convention, without correcting the mass twice. Molarity requires the molecular weight of the confirmed form; do not borrow a value from a related analogue.
Separate functional testing from IGF-1
Direct tesamorelin experiments can use a defined GHRH-receptor system with an appropriate signaling endpoint or a GH-secretion model. IGF-1 in a complex biological system is a downstream endpoint, not a direct measure of stock chemical integrity. Control receptor expression, cell condition and incubation time. For LC-MS or HPLC, establish how excipients affect extraction and detector response. Equal nominal peptide content in different formulations does not guarantee equal analytical recovery.
The N-terminal modification belongs in identity testing
The hexenoyl group on N-terminal Tyr distinguishes tesamorelin from native GHRH. A method measuring only a shared peptide-region signal may not distinguish the intended analyte from related material. Batch checks require demonstrated specificity for the complete modified form. Check analyte extraction from protein- and excipient-containing matrices. For antibody assays, establish cross-reactivity with GHRH and fragments. An unqualified positive immune signal is insufficient evidence of intact tesamorelin after storage.
Stock and temperature questions
Can a stabilized medicine’s room-temperature label be followed? It is not evidence for a different dry laboratory material; store long-term stocks under their own specification, generally frozen. Does clarity establish receptor-assay suitability? It establishes neither an intact N-terminal modification nor activity. Should concentration be increased when an old solution gives less signal? First check chemical recovery and a fresh functional control. Additional nominal mass could otherwise conceal a matrix, receptor or degradation problem.
Formulation determines the storage-validation plan
Egrifta SV and WR demonstrate why stabilizers cannot be ignored. Sucrose/polysorbate-containing powder and hydroxypropyl-betadex material can have different specifications; pure laboratory peptide inherits neither automatically. Store dry research stocks at the supplier’s freezer temperature without condensation. For solutions, assess recovery of the modified molecule, additive compatibility with the GHRH-receptor assay and behavior throughout the working interval. If freezing is supported, size aliquots for the experiment and record repeat thaws separately from preparation date.
End of article
Tesamorelin
for laboratory research
Packs and current prices on the product page.